hpv
genotyp
identifi
differ
epitheli
tropism
infect
cutan
hpv
type
caus
benign
cutan
wart
epidermodysplasia
verruciformi
mucos
hpv
type
infect
upper
part
respiratori
tract
oral
caviti
epithelium
anogenit
region
lowrisk
anogenit
hpv
caus
genit
wart
wherea
highrisk
hpv
associ
progress
carcinoma
cervix
vulva
vagina
peni
anu
oropharynx
cervic
cancer
third
common
cancer
worldwid
cervic
cancer
caus
infect
hpv
type
current
two
licens
hpv
major
capsid
protein
viruslik
particl
vlp
base
vaccin
cervarix
bival
vaccin
gardasil
quadrival
vaccin
although
crossreact
observ
close
relat
hpv
genotyp
protect
provid
upon
vaccin
hpv
vlp
vaccin
larg
hpv
typespecif
indic
vaccin
provid
littl
crossprotect
hpv
type
cover
vaccin
limit
crossprotect
capac
vaccin
make
necessari
develop
panhpv
vaccin
vaccin
recombin
minor
capsid
protein
peptid
deriv
result
product
crossneutr
antibodi
protect
anim
model
context
nativ
virion
poorli
immunogen
neither
natur
infect
immun
hpv
vlp
elicit
antibodi
respons
studi
show
poorli
expos
surfac
virion
gener
accept
hpv
viru
bind
heparin
sulfat
moieti
basement
membran
capsid
undergo
conform
chang
expos
amino
terminu
expos
nterminu
suscept
proteas
cleavag
thu
expos
epitop
near
nterminu
protein
sever
region
nterminu
target
neutral
antibodi
prevent
virus
transfer
basement
membran
unidentifi
receptor
epitheli
cell
major
crossneutr
epitop
locat
amino
acid
repres
attract
candid
antigen
broadli
protect
vaccin
neutral
titer
produc
vaccin
consider
lower
induc
vlp
vaccin
particularli
heterolog
hpv
type
therefor
like
vaccin
effect
immunogen
enhanc
bcell
activ
initi
follow
engag
bcell
receptor
bcr
specif
antigen
larg
antigen
immun
complex
virus
present
b
cell
effici
small
solubl
molecul
unlik
tcell
receptor
tcr
recogn
process
epitop
context
major
histocompat
complex
molecul
bcr
may
recogn
unprocess
antigen
present
surfac
antigen
present
cell
apc
display
multival
epitop
expos
region
vlp
deriv
papillomaviru
bacteriophag
adenoassoci
viru
surfac
region
bacteri
thioredoxin
shown
induc
enhanc
epitopedirect
antibodi
respons
broadli
protect
immun
fc
receptor
igg
express
dendrit
cell
dc
apc
bind
intern
antigenigg
immun
complex
via
interact
igg
results
enrich
exogen
antigen
dc
facilit
dc
matur
antigenspecif
cell
respons
humor
respons
recombin
antigenimmunoglobin
fcfusion
protein
shown
increas
immunogen
fuse
antigen
elicit
neutral
antibodi
respons
hiv
protect
immun
virul
herp
simplex
viru
influenza
virus
ebola
virus
studi
show
first
time
fuse
aa
epitop
repeat
recombin
ligand
design
see
figur
could
significantli
increas
immunogen
peptid
induc
crossneutr
antibodi
protect
immun
rang
phylogenet
distant
hpv
type
recombin
ligand
fclike
fusion
protein
contain
tandem
repeat
compos
copi
hing
region
human
chain
region
igg
encompass
sequenc
bind
express
peptid
fclike
fusion
protein
antigen
gene
encod
three
repeat
twelv
repeat
aa
epitop
three
amino
acid
linker
glyglypro
fuse
infram
upstream
figur
result
fusion
protein
design
figur
facilit
purif
signal
peptid
sequenc
baculoviru
ad
upstream
fusion
gene
gene
codon
optim
base
codon
usag
bia
cell
sangon
shanghai
subclon
vector
express
secret
protein
baculoviru
express
system
describ
previous
protein
purifi
cultur
supernat
rprotein
sepharos
affin
chromatographi
accord
manufactur
instruct
ge
healthcar
protein
also
express
purifi
scaffold
control
express
analysi
recombin
protein
evalu
sdspage
coomassi
blue
stain
western
blot
dilut
crossneutr
protect
monoclon
antibodi
recogn
residu
gener
provid
richard
roden
previou
report
puriti
purifi
protein
determin
host
cell
protein
hcp
elisa
describ
previous
four
sixweekold
femal
balbc
mice
new
zealand
white
rabbit
purchas
institut
laboratori
anim
scienc
chines
academi
medic
scienc
kept
anim
facil
institut
basic
medic
scienc
chines
academi
medic
scienc
anim
work
done
accord
guidelin
institut
anim
care
use
committe
institut
laboratori
anim
scienc
chines
academi
medic
scienc
experiment
protocol
approv
institut
anim
care
use
committe
group
mice
vaccin
week
nmol
peptid
lifetin
beij
phosphatebuff
salin
pb
formul
complet
freund
adjuv
cfa
prime
dose
incomplet
freund
adjuv
ifa
booster
immun
group
rabbit
vaccin
subcutan
week
nmol
alon
alum
sigmaaldrich
monophosphoryl
lipid
sigmaaldrich
alummpl
adjuv
sera
collect
week
store
pseudovirus
respect
encapsid
report
plasmid
plucf
encod
luciferas
green
fluoresc
protein
gfp
plasmid
clonetech
encod
gfp
produc
cell
previous
describ
minor
modif
prepar
dna
shell
plasmid
report
plasmid
mix
turbofect
thermo
fisher
ml
unsuppl
dmem
ad
cell
suggest
prof
reinhard
kirnbauer
titer
psv
infecti
unit
per
ml
iuml
determin
gfp
express
cell
describ
http
homeccrcancergovlcopseudovirusproductionhtm
express
plasmid
plucf
plasmid
gener
provid
john
schiller
susana
pang
chri
buck
martin
tadahito
kanda
assess
bind
protein
elisa
plate
coat
ng
protein
ng
equival
amount
recombin
protein
mole
basi
peptid
overnight
elisa
perform
previous
describ
briefli
well
block
bovin
serum
albumen
bsa
pbst
room
temperatur
hour
monoclon
antibodi
dilut
ad
well
incub
room
temperatur
hour
wash
well
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
dilut
room
temperatur
hour
plate
develop
addit
gml
ophenylenediamin
dilut
phosphatecitr
buffer
ph
contain
vv
hydrogen
peroxid
enzymat
reaction
stop
addit
solut
contain
plate
read
nm
antibodi
titer
determin
reciproc
highest
serum
dilut
od
greater
higher
control
sera
dilut
measur
crossreact
antibodi
respons
hpv
capsid
antisera
elisa
plate
coat
iu
hpv
psv
depend
psv
stock
encod
gfp
sera
collect
week
assess
endpoint
dilut
elisa
describ
bind
titer
determin
reciproc
highest
serum
dilut
od
greater
higher
control
sera
dilut
statist
signific
determin
oneway
anova
bonferroni
multipl
comparison
test
graphpad
prism
p
valu
consid
statist
signific
hpv
psvbase
neutral
assay
perform
previou
report
pseudoviru
encod
gfp
diluent
serial
dilut
sera
mix
ad
cell
cultur
plate
incub
cell
digest
trypsin
transfer
cell
sort
tube
fluoresc
cell
detect
fluoresc
activ
cell
sort
endpoint
titer
calcul
reciproc
highest
serum
dilut
percent
infect
inhibit
higher
titer
consid
nonsignific
everi
sampl
detect
duplic
statist
signific
determin
oneway
anova
bonferroni
multipl
comparison
test
mice
treat
mg
progesteron
subcutan
four
day
psv
challeng
immun
mice
intravagin
pretreat
igep
sigma
six
hour
prior
psv
challeng
pb
inject
femal
mice
use
control
psv
prepar
contain
iu
psv
encapsid
report
plasmid
plucf
carboxymethyl
cellulos
cmc
sigma
intravagin
instil
use
positivedisplac
pipett
fortyeight
hour
postpsv
challeng
mice
vagin
instil
mg
cellcyto
life
scienc
three
minut
later
luciferas
signal
acquir
min
biofluoresc
imag
bfi
system
lb
nightowl
ii
berthold
technolog
analyz
indigo
softwar
berthold
technolog
statist
signific
determin
onetail
unpair
ttest
first
examin
express
protein
cultur
medium
sdspage
sinc
express
secret
protein
observ
kda
kda
band
coomassi
blue
stain
figur
confirm
western
blot
figur
recombin
protein
highli
express
approxim
mg
mg
obtain
per
ml
cultur
medium
protein
purifi
rprotein
affin
chromatographi
puriti
analyz
sdspage
coomassi
blue
stain
figur
hcp
elisa
protein
load
singl
band
observ
sampl
indic
stabl
two
addit
small
band
also
observ
sampl
indic
partial
degrad
small
band
reactiv
antibodi
western
blot
shown
hcp
elisa
found
puriti
purifi
character
stabil
kept
purifi
protein
room
temperatur
day
found
singl
band
sampl
sdspage
coomassi
blue
stain
shown
taken
togeth
conclud
fusion
protein
highli
express
simpli
purifi
stabil
vitro
assess
immunogen
protein
first
show
strongli
bound
peptid
scaffold
control
figur
indic
epitop
protein
well
expos
recogn
antibodi
next
ask
whether
protein
abl
induc
crossreact
antibodi
respons
goal
develop
vaccin
induc
broadest
crossreact
diverg
hpv
type
panel
hpv
psv
includ
five
common
oncogen
type
common
type
found
benign
genit
wart
caus
epidermodysplasia
verruciformi
use
coat
elisa
plate
sera
collect
week
four
immun
mice
hpv
capsidreact
antibodi
titer
measur
endpoint
dilut
elisa
bind
titer
psv
type
antisera
significantli
higher
antisera
p
figur
suggest
scaffold
enhanc
immunogen
fuse
antigen
also
observ
stronger
antibodi
respons
induc
p
may
due
instabl
figur
thu
data
show
fusion
protein
highli
immunogen
induc
broad
crossreact
antibodi
diverg
hpv
type
hpv
capsidbas
elisa
assay
detect
nonneutr
neutral
antibodi
neutral
antibodi
thought
primari
immun
mechan
protect
hpv
vaccin
thu
examin
crossneutr
antibodi
respons
induc
protein
use
psvbase
vitro
neutral
assay
proofofconcept
panel
psv
encod
gfp
diverg
hpv
includ
use
neutral
assay
although
crossneutr
antibodi
level
antisera
third
immun
low
titer
shown
observ
broad
crossneutr
antibodi
respons
induc
fourth
immun
figur
mean
neutral
antibodi
titer
antisera
respect
significantli
higher
antisera
p
induc
weak
neutral
antibodi
respons
mean
titer
neutral
antibodi
titer
heterolog
psv
antisera
although
elicit
significantli
higher
crossreact
antibodi
respons
measur
hpv
capsidbas
elisa
assay
figur
signific
differ
crossneutr
antibodi
titer
antisera
p
suggest
major
serum
antibodi
induc
neutral
antibodi
nt
detect
neutral
antibodi
scaffold
control
antisera
shown
collect
show
freund
adjuv
vaccin
induc
broad
crossneutr
antibodi
respons
mice
given
broad
crossneutr
antibodi
respons
elicit
freund
adjuv
protein
mice
next
examin
vivo
protect
multipl
hpv
type
use
vagin
challeng
assay
mice
immun
formul
freund
adjuv
four
time
interv
eleven
month
first
immun
mice
vagin
challeng
diverg
psv
encod
luciferas
consist
rel
highlevel
crossneutr
antibodi
antisera
figur
mice
immun
complet
protect
challeng
figur
p
figur
p
figur
p
figur
p
figur
p
figur
p
wherea
mean
luminesc
signal
mice
immun
scaffold
compar
pb
control
mice
thu
data
demonstr
vaccin
could
provid
substanti
protect
divers
type
hpv
psv
evalu
potenc
potenti
clinic
applic
fusion
protein
examin
immun
respons
induc
formul
fda
approv
adjuv
alummpl
anoth
anim
model
new
zealand
white
rabbit
two
rabbit
vaccin
either
alon
formul
alummpl
accord
previou
studi
sera
collect
fourth
immun
analyz
psvbase
vitro
neutral
assay
result
shown
tabl
neutral
antibodi
titer
psv
type
alon
antisera
observ
neutral
antibodi
respons
antisera
rabbit
immun
formul
alummpl
neutral
antibodi
titer
two
rabbit
less
neutral
antibodi
titer
psv
type
notic
crossneutr
antibodi
respons
rabbit
weaker
mice
may
due
fact
alummpl
adjuv
use
rabbit
less
effect
freund
adjuv
use
mice
addit
report
antigen
dose
use
rabbit
usual
mice
dose
rabbit
mice
thu
rel
lower
dose
inject
rabbit
may
also
caus
weaker
crossneutr
antibodi
respons
mice
nevertheless
accumul
data
show
induc
crossneutr
antibodi
two
differ
anim
model
formul
alummpl
freund
adjuv
neutral
antibodi
bind
linear
epitop
aa
describ
passiv
transfer
aa
antiserum
antibodi
shown
protect
mice
psv
infect
suggest
neutral
antibodi
induc
epitop
suffici
vivo
protect
report
sera
mice
immun
tandem
repeat
aa
deriv
differ
hpv
type
adjuv
could
neutral
hpv
psv
type
type
studi
fuse
three
repeat
aa
modifi
fc
gener
fusion
protein
highli
express
simpli
purifi
high
puriti
rel
stabl
vitro
importantli
immun
freund
adjuv
elicit
broad
neutral
antibodi
respons
hpv
type
mice
induct
longterm
broadli
protect
immun
clinic
relev
hpv
type
goal
pan
hpv
vaccin
develop
similar
present
epitop
surfac
vlp
shown
induc
endur
protect
antibodi
month
vaccin
result
also
show
broadli
protect
immun
induc
freund
adjuv
sustain
least
month
first
immun
highlight
epitopebas
protein
vaccin
abl
induc
longlast
protect
immun
epitop
properli
deliv
current
studi
use
modifi
fc
scaffold
display
epitop
observ
strong
effect
scaffold
enhanc
immun
respons
induc
epitop
fc
igg
consid
import
fusion
tag
coexpress
sever
viral
protein
promot
correct
fold
fusion
protein
facilit
purif
enhanc
bind
apc
express
improv
immunogen
fuse
protein
previou
studi
show
recombin
protein
fuse
antigen
protein
human
serum
albumin
domain
clostrid
botulinum
neurotoxin
could
effect
target
class
apc
elicit
enhanc
antigenreact
antibodi
respons
thu
think
enhanc
immun
induc
may
result
target
antigen
deliveri
apc
exclud
mechan
contribut
enhanc
immun
respons
prolong
serum
halflif
fcfusion
protein
addit
deriv
human
specul
administr
contain
modifi
human
fc
human
may
result
better
immun
respons
mice
human
fc
bind
human
immun
cell
macrophag
dc
effici
thu
contribut
enhanc
immun
previou
studi
shown
immunogen
epitop
rel
low
studi
fail
detect
neutral
antibodi
antisera
mice
immun
alon
four
time
shown
may
mainli
due
weak
immunogen
epitop
result
consist
previou
report
chimer
adenoassoci
viruslik
particl
bear
epitop
also
fail
induc
neutral
antibodi
immun
alon
concaten
multityp
fusion
protein
shown
elicit
broad
neutral
antibodi
respons
recombin
deriv
singl
hpv
type
thioredoxin
fusion
protein
multipl
copi
peptid
induc
stronger
immunogen
singl
copi
peptid
studi
also
gener
protein
contain
copi
epitop
unfortun
due
poor
protein
stabil
induc
lowerlevel
neutral
antibodi
nondetect
crossneutr
antibodi
hpv
type
consist
observ
jagu
et
al
found
aa
unstabl
peptid
produc
much
weaker
crossneutr
antibodi
respons
aa
stabl
peptid
contain
amount
epitop
suggest
essenti
role
stabil
antigen
protein
vaccin
efficaci
specul
vaccin
potenc
enhanc
stabl
protein
contain
much
epitop
multipl
hpv
type
develop
worthi
note
unlik
freund
adjuv
immun
mice
alummpl
adjuv
immun
rabbit
induc
lowtit
neutral
antibodi
adjuv
antigen
dose
anim
model
vaccin
scaffold
contribut
final
antibodi
respons
exampl
vlp
bovin
papillomaviru
vlp
scaffold
formul
freund
adjuv
cfaifa
induc
much
higher
neutral
antibodi
titer
hpv
type
formul
alummpl
furthermor
even
use
adjuv
alummpl
neutral
antibodi
titer
hpv
type
much
higher
mice
receiv
dose
vlp
rabbit
receiv
dose
dose
mice
studi
adjuv
use
rabbit
alummpl
less
effect
use
mice
freund
adjuv
use
dose
nmol
rabbit
mice
nmol
also
notic
crossneutr
capac
alummpl
adjuv
rabbit
studi
lower
alummpl
adjuv
use
papillomaviru
vlp
platform
display
papillomaviru
vlp
good
adjuv
highli
immunogen
surfac
characterist
moreov
theoret
copi
epitop
surfac
expos
per
chimer
copi
epitop
surfac
expos
per
protein
thu
reason
differenti
broad
like
result
usag
differ
scaffold
display
epitop
taken
togeth
data
demonstr
modifi
human
fc
use
scaffold
display
antigen
induc
crossneutr
antibodi
protect
immun
diverg
human
papillomaviru
type
type
fusion
protein
express
high
yield
easili
purifi
high
puriti
therefor
deliveri
antigen
modifi
fc
scaffold
open
new
avenu
panhpv
vaccin
develop
